Table 2.

Overall survival estimates HPV+/p16+ and HPV–/p16– patients

	Eastern Denmark	Karolinska, Sweden	Giessen, Germany	The Predictr Consortium, UK
OS	HPV+/p16+	HPV+/p16+	HPV+/p16+	HPV+/p16+
1-year	95% (93–96%)	96% (94–98%)	91% (84–98%)	97% (95–99%)
3-year	86% (84–89%)	88% (85–91%)	84% (75–93%)	87% (83–91%)
5-year	80% (77–83%)	81% (77–85%)	81% (72–91%)	82% (77–87%)
OS	HPV–/p16–	HPV–/p16–	HPV–/p16–	HPV–/p16–
1-year	71% (67–75%)	69% (60–80%)	76% (71–82%)	74% (67–82%)
3-year	46% (41–51%)	48% (39–60%)	47% (41–54%)	52% (44–62%)
5-year	34% (29–39%)	38% (29–49%)	35% (30–42%)	42% (34–52%)
Censored cases	n = 888 (63.8%)	n = 389 (71.9%)	n = 164 (45.7%)	n = 420 (62.6%)

OS overall survival